What caused Pfizer's operating profit surge in Q3 2024?

Pfizer's operating profit surge in Q3 2024 can be attributed to several key factors:

1. **Revenue Growth**: Total revenue for the quarter was $3.19 billion, with a year-on-year growth value. This increase in revenue contributes directly to a higher operating profit.
2. **Eliquis and Vyndaqel Sales**: The sales of Eliquis, a blood thinner, rose by 7% to nearly $1.9 billion, and the revenue from the heart treatment Vyndaqel increased by 69% to $1.32 billion. These significant increases in sales of key products contribute positively to the operating profit.
3. **Cost Management**: Pfizer's adjusted selling, informational, and administrative (SI&A) expenses rose by 8% to $3.67 billion. Despite this increase, the company's ability to manage costs effectively allows for a larger portion of revenue to translate into profit.

In summary, Pfizer's operating profit surge in Q3 2024 is driven by revenue growth, particularly from the sales of Eliquis and Vyndaqel, and effective cost management.

|code|Ticker|Name|Date|Net Income YoY|Operating Income YoY|Total Revenue YoY|Operating Income|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2023 Q4|-167.19312275089965|-178.93328235519022|-40.01646768217373|-4.129E9|1.457E10|-3.361E9|169|
|PFE|PFE.N|Pfizer|2024 Q1|-43.79049676025918|-45.438596491228076|-19.51206318294926|3.421E9|1.4879E10|3.123E9|169|
|PFE|PFE.N|Pfizer|2024 Q2|-97.9469632164243|-104.58351696782724|2.121934343046052|-1.04E8|1.3283E10|4.8E7|169|
|PFE|PFE.N|Pfizer|2024 Q3|288.25757575757575|240.66229116945107|31.21340152694389|4.715E9|1.7702E10|4.473E9|169|